Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Key Points Calreticulin mutants responsible for myeloproliferative neoplasms specifically activate the thrombopoietin receptor and in turn JAK2. Activation of the thrombopoietin receptor requires the glycan binding site and a novel C-terminal tail of the mutant calreticulin.

Original publication

DOI

10.1182/blood-2015-11-681932

Type

Journal article

Journal

Blood

Publisher

American Society of Hematology

Publication Date

10/03/2016

Volume

127

Pages

1325 - 1335